Chronic Hepatitis B Virus Pipeline Analysis, 2024 Updates | Latest FDA, EMA, and PMDA Approvals | GSK, Ascletis Pharma, Shanghai HEP Pharma, Romark Lab, Qilu Pharma, Golden Biotech, Sunshine Lake

 Breaking News
  • No posts were found

Chronic Hepatitis B Virus Pipeline Analysis, 2024 Updates | Latest FDA, EMA, and PMDA Approvals | GSK, Ascletis Pharma, Shanghai HEP Pharma, Romark Lab, Qilu Pharma, Golden Biotech, Sunshine Lake

March 02
09:30 2024
Chronic Hepatitis B Virus Pipeline Analysis, 2024 Updates | Latest FDA, EMA, and PMDA Approvals | GSK, Ascletis Pharma, Shanghai HEP Pharma, Romark Lab, Qilu Pharma, Golden Biotech, Sunshine Lake
(Las Vegas, Nevada, United States) As per DelveInsight’s assessment, globally, Chronic Hepatitis B Virus pipeline constitutes 50+ key companies continuously working towards developing 55+ Chronic Hepatitis B Virus treatment therapies, analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments analyzes DelveInsight.

The Chronic Hepatitis B Virus Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers acquisition, funding, designations, and other product-related details.

 

Chronic Hepatitis B Virus Pipeline Insight, 2024 report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Chronic Hepatitis B Virus Market.

 

Some of the key takeaways from the Chronic Hepatitis B Virus Pipeline Report: 

  • Companies across the globe are diligently working toward developing novel Chronic Hepatitis B Virus treatment therapies with a considerable amount of success over the years. 
  • Chronic Hepatitis B Virus companies working in the treatment market are Precision Biosciences, Silverback Therapeutics, GSK, Drug Farm, Arbutus bio, Dicerna Pharmaceuticals, Roche, Ligand Pharmaceuticals, Dong-A ST Co., Vir Biotechnology, Arbutus Biopharma, and others, are developing therapies for the Chronic Hepatitis B Virus treatment 
  • Emerging Chronic Hepatitis B Virus therapies in the different phases of clinical trials are- PBGENE-HBV, SBT8230, GSK3965193, DF 006, AB 729, RG6346, RG7854, Bepirovirsen, Pradefovir, DA 2802, VIR-2218, AB-729, and others are expected to have a significant impact on the Chronic Hepatitis B Virus market in the coming years.   
  • In January 2022,  VBI Vaccines has announced the commencement of dosing for the first participant in a subsequent Phase 2a/2b clinical study evaluating VBI-2601 (also referred to as BRII-179), an immunotherapeutic candidate specifically crafted for the treatment of chronic hepatitis B virus (HBV).
  • In March 2022, Brii Biosciences Limited has presented recent results from a Phase II trial involving Chinese patients with chronic hepatitis B virus (HBV) infection, at the 31st Conference of the Asian Pacific Association for the Study of the Liver (APASL) in 2022. The study focused on BRII-835 (VIR-2218), an experimental small interfering ribonucleic acid (siRNA) utilizing RNA interference (RNAi). The data revealed a dose-dependent reduction in hepatitis B surface antigen (HBsAg) among patients receiving two doses of BRII-835 (VIR-2218), regardless of their HBeAg status. Furthermore, the treatment exhibited favorable tolerability, with all reported treatment-emergent adverse events (TEAEs) being mild or moderate, and no clinically significant alanine transaminase (ALT) elevations were observed.
  • In March 2022, Aligos Therapeutics has halted the progress of ALG-020572, an investigational drug for individuals with chronic hepatitis B (CHB). This decision comes in the wake of a serious adverse event (SAE) involving a participant in the initial CHB cohort of Study ALG-020572-401, leading to a brief hospitalization. The affected individual displayed a notable increase in alanine aminotransferase (ALT) levels after undergoing multiple administrations of the 210 mg treatment. Aligos emphasized that this occurrence was among four cases in the chronic hepatitis B (CHB) cohort showing potentially drug-related ALT flares, indicating signs of liver toxicity.

 

Chronic Hepatitis B Virus Overview

Chronic Hepatitis B Virus (HBV) infection is a long-term, persistent infection caused by the hepatitis B virus. Hepatitis B is a virus that primarily affects the liver and can lead to both acute and chronic forms of hepatitis.

 

Get a Free Sample PDF Report to know more about Chronic Hepatitis B Virus Pipeline Therapeutic Assessment-

https://www.delveinsight.com/report-store/chronic-hepatitis-b-virus-pipeline-insight

 

Emerging Chronic Hepatitis B Virus Drugs Under Different Phases of Clinical Development Include:

  • PBGENE-HBV: Precision Biosciences
  • SBT8230: Silverback Therapeutics
  • GSK3965193: GSK
  • DF 006: Drug Farm
  • AB 729: Arbutus bio
  • RG6346: Dicerna Pharmaceuticals
  • RG7854: Roche
  • Bepirovirsen: GSK
  • Pradefovir: Ligand Pharmaceuticals
  • Pradefovir: Ligand Pharmaceuticals
  • DA 2802: Dong-A ST Co.
  • VIR-2218: Vir Biotechnology
  • AB-729: Arbutus Biopharma

 

Chronic Hepatitis B Virus Route of Administration

Chronic Hepatitis B Virus pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs, such as 

  • Oral
  • Parenteral
  • Intravenous
  • Subcutaneous
  • Topical

 

Chronic Hepatitis B Virus Molecule Type

Chronic Hepatitis B Virus Products have been categorized under various Molecule types, such as

  • Monoclonal Antibody
  • Peptides
  • Polymer
  • Small molecule
  • Gene therapy 

 

Chronic Hepatitis B Virus Pipeline Therapeutics Assessment

  • Chronic Hepatitis B Virus Assessment by Product Type
  • Chronic Hepatitis B Virus By Stage and Product Type
  • Chronic Hepatitis B Virus Assessment by Route of Administration
  • Chronic Hepatitis B Virus By Stage and Route of Administration
  • Chronic Hepatitis B Virus Assessment by Molecule Type
  • Chronic Hepatitis B Virus by Stage and Molecule Type

 

DelveInsight’s Chronic Hepatitis B Virus Report covers around 55+ products under different phases of clinical development like

  • Late-stage products (Phase III)
  • Mid-stage products (Phase II)
  • Early-stage product (Phase I)
  • Pre-clinical and Discovery stage candidates
  • Discontinued & Inactive candidates
  • Route of Administration

 

Further Chronic Hepatitis B Virus product details are provided in the report. Download the Chronic Hepatitis B Virus pipeline report to learn more about the emerging Chronic Hepatitis B Virus therapies

 

Some of the key companies in the Chronic Hepatitis B Virus Therapeutics Market include:

Key companies developing therapies for Chronic Hepatitis B Virus are – Ascletis Pharmaceuticals, Shanghai HEP Pharmaceutical, Romark Laboratories, Qilu Pharmaceutical, Golden Biotechnology, Sunshine Lake Pharma, Ascentage Pharma, Vir Biotechnology, GlaxoSmithKline, Janssen Sciences, Henlix, Enyo Pharma, Gilead Sciences, Dong-A ST Co., Ltd., Assembly Biosciences, Arbutus Biopharma, Vir Biotechnology, Antios Therapeutics, Tasly Tianjin Biopharmaceutical, Brii Biosciences, Vaxine Pty Ltd, Vaccitech limited, Zhejiang Palo Alto Pharmaceuticals, Suzhou Ribo Life Science, PharmaEssentia, Nucorion Pharmaceuticals, Jiangsu HengRui Medicine, Enanta Pharmaceuticals, and others.

 

Chronic Hepatitis B Virus Pipeline Analysis:

The Chronic Hepatitis B Virus pipeline report provides insights into 

  • The report provides detailed insights about companies that are developing therapies for the treatment of Chronic Hepatitis B Virus with aggregate therapies developed by each company for the same.
  • It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Chronic Hepatitis B Virus Treatment.
  • Chronic Hepatitis B Virus key companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
  • Chronic Hepatitis B Virus Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type. 
  • Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Chronic Hepatitis B Virus market.

The report is built using data and information traced from the researcher’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.

 

Download Sample PDF Report to know more about Chronic Hepatitis B Virus drugs and therapies

 

Chronic Hepatitis B Virus Pipeline Market Drivers

  • High prevalence of chronic HBV infection, increasing Research and development in Chronic Hepatitis B are some of the important factors that are fueling the Chronic Hepatitis B Virus Market.

 

Chronic Hepatitis B Virus Pipeline Market Barriers

  • However, high cost of treatment, limited access to the diagnosis of hepatitis B and other factors are creating obstacles in the Chronic Hepatitis B Virus Market growth.

 

Scope of Chronic Hepatitis B Virus Pipeline Drug Insight    

  • Coverage: Global
  • Key Chronic Hepatitis B Virus Companies: Precision Biosciences, Silverback Therapeutics, GSK, Drug Farm, Arbutus bio, Dicerna Pharmaceuticals, Roche, Ligand Pharmaceuticals, Dong-A ST Co., Vir Biotechnology, Arbutus Biopharma, and others
  • Key Chronic Hepatitis B Virus Therapies: PBGENE-HBV, SBT8230, GSK3965193, DF 006, AB 729, RG6346, RG7854, Bepirovirsen, Pradefovir, DA 2802, VIR-2218, AB-729, and others
  • Chronic Hepatitis B Virus Therapeutic Assessment: Chronic Hepatitis B Virus current marketed and Chronic Hepatitis B Virus emerging therapies
  • Chronic Hepatitis B Virus Market Dynamics: Chronic Hepatitis B Virus market drivers and Chronic Hepatitis B Virus market barriers 

 

Request for Sample PDF Report for Chronic Hepatitis B Virus Pipeline Assessment and clinical trials

 

Table of Contents

1. Chronic Hepatitis B Virus Report Introduction

2. Chronic Hepatitis B Virus Executive Summary

3. Chronic Hepatitis B Virus Overview

4. Chronic Hepatitis B Virus- Analytical Perspective In-depth Commercial Assessment

5. Chronic Hepatitis B Virus Pipeline Therapeutics

6. Chronic Hepatitis B Virus Late Stage Products (Phase II/III)

7. Chronic Hepatitis B Virus Mid Stage Products (Phase II)

8. Chronic Hepatitis B Virus Early Stage Products (Phase I)

9. Chronic Hepatitis B Virus Preclinical Stage Products

10. Chronic Hepatitis B Virus Therapeutics Assessment

11. Chronic Hepatitis B Virus Inactive Products

12. Company-University Collaborations (Licensing/Partnering) Analysis

13. Chronic Hepatitis B Virus Key Companies

14. Chronic Hepatitis B Virus Key Products

15. Chronic Hepatitis B Virus Unmet Needs

16 . Chronic Hepatitis B Virus Market Drivers and Barriers

17. Chronic Hepatitis B Virus Future Perspectives and Conclusion

18. Chronic Hepatitis B Virus Analyst Views

19. Appendix

20. About DelveInsight

 

 

About DelveInsight

 

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate business growth and overcome challenges with a practical approach.

Media Contact
Company Name: DelveInsight
Contact Person: Gaurav Bora
Email: Send Email
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/

Related Articles

Categories